Skip to main content
. 2020 Sep 21;18(1):401–411. doi: 10.1007/s13311-020-00923-5

Fig. 3.

Fig. 3

Effect of JM4 on clinical scores in long-term PLP-induced relapsing–remitting EAE. GFAP-luc/SJL mice were treated for 12 days with JM4 (5 μg IV) starting on day 9. Average clinical scores in the JM4-treated group, from day 60 onward, remained remarkably reduced compared to the sham-treated group for over 5 months (n = 4 JM4 treated, n = 5 sham treated, p < 0.05)